IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 335 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,396,948 | +13.8% | 34,047 | -0.9% | 0.05% | +3.9% |
| Q1 2023 | $1,227,312 | +62.7% | 34,340 | +71.9% | 0.05% | +13.3% |
| Q4 2022 | $754,531 | +162.9% | 19,977 | +207.7% | 0.04% | +150.0% |
| Q3 2022 | $287,000 | -53.6% | 6,493 | -61.1% | 0.02% | -21.7% |
| Q2 2022 | $618,000 | +68.9% | 16,703 | +69.3% | 0.02% | +64.3% |
| Q1 2022 | $366,000 | -65.0% | 9,868 | -71.3% | 0.01% | -70.2% |
| Q4 2021 | $1,046,000 | +87.1% | 34,380 | +106.2% | 0.05% | +46.9% |
| Q3 2021 | $559,000 | -57.4% | 16,672 | -42.8% | 0.03% | -50.8% |
| Q1 2021 | $1,311,000 | +225.3% | 29,160 | +309.6% | 0.06% | +282.4% |
| Q4 2020 | $403,000 | -40.4% | 7,120 | -50.1% | 0.02% | -46.9% |
| Q3 2020 | $676,000 | +88.3% | 14,257 | +87.6% | 0.03% | +23.1% |
| Q1 2020 | $359,000 | -56.8% | 7,598 | -44.7% | 0.03% | -29.7% |
| Q4 2019 | $831,000 | -62.4% | 13,751 | -49.4% | 0.04% | -72.4% |
| Q1 2019 | $2,208,000 | – | 27,200 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,510,173 | $159,221,447 | 8.52% |
| Bellevue Group AG | 9,233,700 | $418,840,632 | 6.75% |
| Deep Track Capital, LP | 2,834,069 | $128,553,370 | 4.96% |
| BVF INC/IL | 4,004,613 | $181,649,246 | 4.90% |
| Sicart Associates LLC | 203,132 | $9,214,068 | 3.61% |
| Camber Capital Management LP | 2,250,000 | $102,060 | 3.36% |
| Privium Fund Management B.V. | 228,493 | $10,364,443 | 3.08% |
| Orbimed Advisors | 2,169,500 | $98,408,520 | 2.09% |
| SECTOR GAMMA AS | 165,616 | $7,512,342 | 1.92% |
| TANAKA CAPITAL MANAGEMENT INC | 14,612 | $663 | 1.89% |